# NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)

> **NCT03968354** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 50 (estimated)

## Conditions studied

- Diabetes type2
- NASH - Nonalcoholic Steatohepatitis
- NAFLD

## Interventions

- **BIOLOGICAL:** "Collection of additional blood tubes; Biobanking (plasma, liver tissue).

## Key facts

- **NCT ID:** NCT03968354
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02
- **Primary completion:** 2021-06
- **Final completion:** 2021-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03968354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03968354, "NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03968354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*